ATE356995T1 - Verfahren zur identifizierung von mitteln zur behandlung von diabetes - Google Patents

Verfahren zur identifizierung von mitteln zur behandlung von diabetes

Info

Publication number
ATE356995T1
ATE356995T1 AT02739056T AT02739056T ATE356995T1 AT E356995 T1 ATE356995 T1 AT E356995T1 AT 02739056 T AT02739056 T AT 02739056T AT 02739056 T AT02739056 T AT 02739056T AT E356995 T1 ATE356995 T1 AT E356995T1
Authority
AT
Austria
Prior art keywords
treating diabetes
identifying agents
mnk2b
mnk2a
methods
Prior art date
Application number
AT02739056T
Other languages
English (en)
Inventor
Christina Bendz
Staffan Lake
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20284509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE356995(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Application granted granted Critical
Publication of ATE356995T1 publication Critical patent/ATE356995T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02739056T 2001-06-18 2002-06-18 Verfahren zur identifizierung von mitteln zur behandlung von diabetes ATE356995T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102147A SE0102147D0 (sv) 2001-06-18 2001-06-18 New methods

Publications (1)

Publication Number Publication Date
ATE356995T1 true ATE356995T1 (de) 2007-04-15

Family

ID=20284509

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02739056T ATE356995T1 (de) 2001-06-18 2002-06-18 Verfahren zur identifizierung von mitteln zur behandlung von diabetes

Country Status (13)

Country Link
US (1) US20030022241A1 (de)
EP (1) EP1397681B1 (de)
JP (1) JP4475945B2 (de)
AT (1) ATE356995T1 (de)
AU (1) AU2002311737B2 (de)
CA (1) CA2446284A1 (de)
CY (1) CY1107640T1 (de)
DE (1) DE60218843T2 (de)
DK (1) DK1397681T3 (de)
ES (1) ES2284879T3 (de)
PT (1) PT1397681E (de)
SE (1) SE0102147D0 (de)
WO (1) WO2002103361A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500813A (ja) * 2001-01-12 2005-01-13 エクセリクシス・インコーポレイテッド インスリン受容体シグナル伝達の調節
DE10294485T5 (de) * 2001-10-29 2004-04-29 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Mit Mnk-Kinase homologe Proteine, die in die Regulation der Energiehomöostase und den Organellenmetabolismus involviert sind
US20050202407A1 (en) * 2003-12-01 2005-09-15 Baylor College Of Medicine Methods and assays for screening anti-neoplastic therapeutic agents
JP2008521446A (ja) 2004-12-02 2008-06-26 ユニバーシティ オブ マサチューセッツ グルコース輸送関連遺伝子、ポリペプチド、およびその使用方法
CN101454325A (zh) 2006-03-09 2009-06-10 法马科皮亚公司 用于治疗代谢性疾病的8-杂芳基嘌呤mnk2抑制剂
EP1889847A1 (de) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidine zur pharmazeutischen Anwendung
BR112012021453A2 (pt) 2010-02-26 2017-02-21 Boehringer Ingelheim Int tienopirimidina, sua composição farmacêutica e seu uso
PH12012501693A1 (en) 2010-02-26 2012-11-05 Boehringer Ingelheim Int 4 - [cycloalkyloxy (hetero) arylamino] thieno [2,3 - d] pyrimidines having mnkl/mnk2 inhibiting activity for pharmaceutical compositions
EP2539344B1 (de) 2010-02-26 2014-10-15 Boehringer Ingelheim International GmbH Halogen oder cyano substituierte thieno[2,3-d]pyrimidine mit mnk1/mnk2-hemmender wirkung für pharmazeutische zusammensetzungen
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
ES2635262T3 (es) 2012-11-09 2017-10-03 Evotec International Gmbh Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas
AU2014359456B2 (en) 2013-12-04 2019-01-24 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
WO2015091156A1 (en) 2013-12-17 2015-06-25 Boehringer Ingelheim International Gmbh Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions
CA2944103A1 (en) 2014-05-07 2015-11-12 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
MX2018004879A (es) 2015-10-22 2019-02-28 Selvita S A Nuevos derivados de piridona y su uso como inhibidores de quinasas.
CN109069865A (zh) * 2016-03-31 2018-12-21 南澳大利亚卫生与医学研究所有限公司 抑制高脂肪饮食相关病症的方法
WO2022076812A2 (en) 2020-10-09 2022-04-14 University Of Massachusetts Targeting nrip1 to alleviate metabolic disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874231A (en) * 1994-08-22 1999-02-23 Mcgill University Methods of screening for non-hormone compounds which effect modulation of polypeptide translation
US6057117A (en) * 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3

Also Published As

Publication number Publication date
PT1397681E (pt) 2007-06-19
SE0102147D0 (sv) 2001-06-18
DE60218843T2 (de) 2007-07-12
EP1397681B1 (de) 2007-03-14
DE60218843D1 (de) 2007-04-26
JP2005500033A (ja) 2005-01-06
JP4475945B2 (ja) 2010-06-09
DK1397681T3 (da) 2007-07-16
CA2446284A1 (en) 2002-12-27
AU2002311737B2 (en) 2007-06-21
EP1397681A1 (de) 2004-03-17
CY1107640T1 (el) 2013-04-18
WO2002103361A1 (en) 2002-12-27
ES2284879T3 (es) 2007-11-16
US20030022241A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE342719T1 (de) Iontophoretische verabreichung von rotigotin zur behandlung der parkinson'schen krankheit
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
ATE359079T1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
ATE382347T1 (de) Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE364180T1 (de) Screeningverfahren mit bnpi und dnpi
DE602004015321D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
DE60122781D1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
ATE380884T1 (de) Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind.
DE60233353D1 (de) Verfahren zur behandlung von halitose
DE60213968D1 (de) Blutgerinnungsfaktor xiii zur behandlung von plättchenfunktionsstörungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1397681

Country of ref document: EP

RZN Patent revoked